PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 10, 2019
RoSPA Recognizes Catalent for Health and Safety Practices
Author(s)Pharmaceutical Technology Editors
Catalent has revealed that it is the recipient of a silver award from the Royal Society for the Prevention of Accidents (RoSPA) in recognition of its health and safety practices.
Advertisement
In a May 7, 2019 press release, Catalent has revealed that it is the recipient of a silver award from the Royal Society for the Prevention of Accidents (RoSPA) in recognition of its health and safety practices.
Julia Small, head of qualifications, awards, and events, RoSPA said, “The RoSPA Awards have become the key fixture in the health and safety calendar, with new sponsors and new awards this year including the Leisure Safety Awards, the Safe@Work Safe@Home Award, and the Inspiration Awards. Highly-respected, with almost 2000 entrants every year, RoSPA award winners benefit from the wide-ranging rewards of improved sector reputation.”
“This is a big achievement for the Catalent team, who strive to continuously improve our Environment, Health, and Safety Management System,” commented Pete Williams, vice-president, global EHS, security and reliability excellence at Catalent. “This award reflects Catalent’s commitment to the environment and the health and safety of its employees, and the engagement of our employees in helping us to make Catalent a safer place to work.”
The RoSPA awards recognize achievements in health and safety management systems in the United Kingdom. This year’s awards ceremonies will be held on three separate evenings in Birmingham, London, and Glasgow. Catalent will be presented with its award on June 18, 2019 at the ExCel Exhibition Center in London.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement